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Radioligand therapy (RLT) using 177Lu-PSMA ligands is
highly effective in metastatic castration-resistant prostate
cancer (mCRPC); however, failure of 177Lu-PSMA RLT
remains challenging as RLT already represents last-line
treatment.
The α-emitter 225Ac provides higher biological effec-
tiveness compared with 177Lu [1]. Several centers report-
ed remarkable response after PSMA-targeted alpha thera-
py (TAT) using 225Ac-PSMA-617 after failure of 177Lu-
PSMA RLT [2, 3]. Here we present encouraging response
to TAT in a patient with advanced mCRPC showing pro-
gression after long-term 177Lu-PSMA RLT (10 cycles).
PSA values are provided under the date of each PSMA-
PET MIP image (A–B using 68Ga-PSMA-11 and E–H
using 18F-PSMA-1007). The patient was referred for
RLT after radical prostatectomy and radiotherapy in
2005, and anti-hormonal therapy started in 2013 due to
biochemical progression. Further progression was ob-
served in February 2017 (A) after 2nd-line anti-hormonal
therapy from 2015 to 2016, 223Ra-Dichloride in 2016, and
docetaxel chemotherapy from 2016 to 2017. Two cycles
of 177Lu-PSMA-617 were highly effective (B). PSA was
still decreasing after two additional 177Lu-PSMA-617 cy-
cles despite increasing PSMA-ligand uptake in PSMA-
PET (C). Maintenance therapy using 177Lu-PSMA-617
was continued until January 2019 with further response
(D and E); however, disease progression occurred after
watchful waiting and two cycles of 177Lu-PSMA-I&T (F
and G). The patient then received two cycles of 225Ac-
PSMA-I&T and showed encouraging response (H). The
main TAT-related side effect was grade 2 xerostomia
(grade 2), which was already preexisting after 10 cycles
of RLT. No TAT-related grade 3/4 hematological side
effects were noted. Further cycles are planned but were
suspended due to the COVID-19 crisis upon patient’s
request.
Different approaches including tandem therapy with 177Lu
or de-escalating doses during consolidation have been pro-
posed for TAT as a trade-off between therapeutic efficacy
and tolerable side effects [2, 4], and further studies investigat-
ing 225Ac-PSMA remain highly important for prostate cancer
theranostics.
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